Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.

Lau D, Kalaitzaki E, Church DN, Pandha H, Tomlinson I, Annels N, Gerlinger M, Sclafani F, Smith G, Begum R, Crux R, Gillbanks A, Wordsworth S, Chau I, Starling N, Cunningham D, Dhillon T.

ESMO Open. 2020 Feb;5(1). pii: e000638. doi: 10.1136/esmoopen-2019-000638.

2.

Estimating the effect of healthcare-associated infections on excess length of hospital stay using inverse-probability weighted survival curves.

Pouwels KB, Vansteelandt S, Batra R, Edgeworth J, Wordsworth S, Robotham JV.

Clin Infect Dis. 2020 Feb 12. pii: ciaa136. doi: 10.1093/cid/ciaa136. [Epub ahead of print]

PMID:
32047916
3.

A Review of Health Economic Studies Comparing Traditional and Massively Parallel Sequencing Diagnostic Pathways for Suspected Genetic Disorders.

Fahr P, Buchanan J, Wordsworth S.

Pharmacoeconomics. 2020 Feb;38(2):143-158. doi: 10.1007/s40273-019-00856-8. Review.

PMID:
31741314
4.

Study protocol for VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study).

Lim E, Batchelor T, Shackcloth M, Dunning J, McGonigle N, Brush T, Dabner L, Harris R, Mckeon HE, Paramasivan S, Elliott D, Stokes EA, Wordsworth S, Blazeby J, Rogers CA; VIOLET Trialists.

BMJ Open. 2019 Oct 14;9(10):e029507. doi: 10.1136/bmjopen-2019-029507.

5.

The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom.

Schwarze K, Buchanan J, Fermont JM, Dreau H, Tilley MW, Taylor JM, Antoniou P, Knight SJL, Camps C, Pentony MM, Kvikstad EM, Harris S, Popitsch N, Pagnamenta AT, Schuh A, Taylor JC, Wordsworth S.

Genet Med. 2020 Jan;22(1):85-94. doi: 10.1038/s41436-019-0618-7. Epub 2019 Jul 30.

6.

A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study.

Harris JM, Brierley RC, Pufulete M, Bucciarelli-Ducci C, Stokes EA, Greenwood JP, Dorman SH, Anderson RA, Rogers CA, Wordsworth S, Berry S, Reeves BC.

Southampton (UK): NIHR Journals Library; 2019 Jul.

7.

Implementation of a genomic medicine multi-disciplinary team approach for rare disease in the clinical setting: a prospective exome sequencing case series.

Taylor J, Craft J, Blair E, Wordsworth S, Beeson D, Chandratre S, Cossins J, Lester T, Németh AH, Ormondroyd E, Patel SY, Pagnamenta AT, Taylor JC, Thomson KL, Watkins H, Wilkie AOM, Knight JC.

Genome Med. 2019 Jul 25;11(1):46. doi: 10.1186/s13073-019-0651-9.

8.

Cardiovascular magnetic resonance in emergency patients with multivessel disease or unobstructed coronary arteries: a cost-effectiveness analysis in the UK.

Stokes EA, Doble B, Pufulete M, Reeves BC, Bucciarelli-Ducci C, Dorman S, Greenwood JP, Anderson RA, Wordsworth S.

BMJ Open. 2019 Jul 11;9(7):e025700. doi: 10.1136/bmjopen-2018-025700.

9.

Antibiotic Review Kit for Hospitals (ARK-Hospital): study protocol for a stepped-wedge cluster-randomised controlled trial.

Walker AS, Budgell E, Laskawiec-Szkonter M, Sivyer K, Wordsworth S, Quaddy J, Santillo M, Krusche A, Roope LSJ, Bright N, Mowbray F, Jones N, Hand K, Rahman N, Dobson M, Hedley E, Crook D, Sharland M, Roseveare C, Hobbs FDR, Butler C, Vaughan L, Hopkins S, Yardley L, Peto TEA, Llewelyn MJ; ARK trial team.

Trials. 2019 Jul 11;20(1):421. doi: 10.1186/s13063-019-3497-y.

10.

Optimising trial designs to identify appropriate antibiotic treatment durations.

Pouwels KB, Yin M, Butler CC, Cooper BS, Wordsworth S, Walker AS, Robotham JV.

BMC Med. 2019 Jun 21;17(1):115. doi: 10.1186/s12916-019-1348-z.

11.

Do health professionals value genomic testing? A discrete choice experiment in inherited cardiovascular disease.

Buchanan J, Blair E, Thomson KL, Ormondroyd E, Watkins H, Taylor JC, Wordsworth S.

Eur J Hum Genet. 2019 Nov;27(11):1639-1648. doi: 10.1038/s41431-019-0452-z. Epub 2019 Jun 11.

12.

Comprehensive ascertainment of bleeding in patients prescribed different combinations of dual antiplatelet therapy (DAPT) and triple therapy (TT) in the UK: study protocol for three population-based cohort studies emulating 'target trials' (the ADAPTT Study).

Pufulete M, Harris J, Sterne JAC, Johnson TW, Lasserson D, Mumford A, Doble B, Wordsworth S, Benedetto U, Rogers CA, Loke Y, Pithara C, Redwood S, Reeves BC.

BMJ Open. 2019 Jun 4;9(6):e029388. doi: 10.1136/bmjopen-2019-029388.

13.

Risk attitudes and sun protection behaviour: Can behaviour be altered by using a melanoma genomic risk intervention?

Morton RL, Asher R, Peyton E, Tran A, Smit AK, Butow PN, Kimlin MG, Dobbinson SJ, Wordsworth S, Keogh L, Cust AE.

Cancer Epidemiol. 2019 Aug;61:8-13. doi: 10.1016/j.canep.2019.05.002. Epub 2019 May 15.

PMID:
31102918
14.

The challenge of antimicrobial resistance: What economics can contribute.

Roope LSJ, Smith RD, Pouwels KB, Buchanan J, Abel L, Eibich P, Butler CC, Tan PS, Walker AS, Robotham JV, Wordsworth S.

Science. 2019 Apr 5;364(6435). pii: eaau4679. doi: 10.1126/science.aau4679. Review.

PMID:
30948524
15.

A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine.

Fahr P, Buchanan J, Wordsworth S.

Appl Health Econ Health Policy. 2019 Aug;17(4):443-452. doi: 10.1007/s40258-019-00474-7. Review.

16.

Correction to: Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Morrell L, Wordsworth S, Schuh A, Middleton MR, Rees S, Barker RW.

BMC Health Serv Res. 2019 Mar 28;19(1):198. doi: 10.1186/s12913-019-4039-8.

17.

Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.

Fragoulakis V, Bartsakoulia M, Díaz-Villamarín X, Chalikiopoulou K, Kehagia K, Ramos JGS, Martínez-González LJ, Gkotsi M, Katrali E, Skoufas E, Vozikis A, John A, Ali BR, Wordsworth S, Dávila-Fajardo CL, Katsila T, Patrinos GP, Mitropoulou C.

Pharmacogenomics J. 2019 Oct;19(5):438-445. doi: 10.1038/s41397-019-0069-1. Epub 2019 Jan 16.

PMID:
30647444
18.

Multi-Centre Micro-Costing of Roux-En-Y Gastric Bypass, Sleeve Gastrectomy and Adjustable Gastric Banding Procedures for the Treatment of Severe, Complex Obesity.

Doble B, Welbourn R, Carter N, Byrne J, Rogers CA, Blazeby JM, Wordsworth S; By-Band-Sleeve Trial Management Group.

Obes Surg. 2019 Feb;29(2):474-484. doi: 10.1007/s11695-018-3553-9.

PMID:
30368646
19.

Evaluating the Outcomes Associated with Genomic Sequencing: A Roadmap for Future Research.

Buchanan J, Wordsworth S.

Pharmacoecon Open. 2019 Jun;3(2):129-132. doi: 10.1007/s41669-018-0101-4. No abstract available.

20.

Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study.

Doble B, Pufulete M, Harris JM, Johnson T, Lasserson D, Reeves BC, Wordsworth S.

Health Qual Life Outcomes. 2018 Sep 20;16(1):191. doi: 10.1186/s12955-018-1019-3. Review.

21.

Using "Big Data" in the Cost-Effectiveness Analysis of Next-Generation Sequencing Technologies: Challenges and Potential Solutions.

Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA.

Value Health. 2018 Sep;21(9):1048-1053. doi: 10.1016/j.jval.2018.06.016. Epub 2018 Aug 17. Erratum in: Value Health. 2019 Apr;22(4):502.

22.

Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions.

Regier DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S.

Value Health. 2018 Sep;21(9):1043-1047. doi: 10.1016/j.jval.2018.06.010. Epub 2018 Aug 18. Review. Erratum in: Value Health. 2019 Apr;22(4):502.

23.

Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions.

Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J.

Value Health. 2018 Sep;21(9):1033-1042. doi: 10.1016/j.jval.2018.06.017. Epub 2018 Aug 8. Review. Erratum in: Value Health. 2019 Mar;22(3):383.

24.

Effect of a Strategy of a Supraglottic Airway Device vs Tracheal Intubation During Out-of-Hospital Cardiac Arrest on Functional Outcome: The AIRWAYS-2 Randomized Clinical Trial.

Benger JR, Kirby K, Black S, Brett SJ, Clout M, Lazaroo MJ, Nolan JP, Reeves BC, Robinson M, Scott LJ, Smartt H, South A, Stokes EA, Taylor J, Thomas M, Voss S, Wordsworth S, Rogers CA.

JAMA. 2018 Aug 28;320(8):779-791. doi: 10.1001/jama.2018.11597.

25.

Cancer as the "perfect storm"? A qualitative study of public attitudes to health conditions.

Morrell L, Ii SS, Wordsworth S, Wilson R, Rees S, Barker R.

Health Sci Rep. 2017 Oct 27;1(1):e16. doi: 10.1002/hsr2.16. eCollection 2018 Jan.

26.

Reducing demand for antibiotic prescriptions: evidence from an online survey of the general public on the interaction between preferences, beliefs and information, United Kingdom, 2015.

Roope LSJ, Tonkin-Crine S, Butler CC, Crook D, Peto T, Peters M, Walker AS, Wordsworth S.

Euro Surveill. 2018 Jun;23(25). doi: 10.2807/1560-7917.ES.2018.23.25.1700424.

27.

Core Items for a Standardized Resource Use Measure: Expert Delphi Consensus Survey.

Thorn JC, Brookes ST, Ridyard C, Riley R, Hughes DA, Wordsworth S, Noble SM, Thornton G, Hollingworth W.

Value Health. 2018 Jun;21(6):640-649. doi: 10.1016/j.jval.2017.06.011. Epub 2017 Sep 1.

28.

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Morrell L, Wordsworth S, Schuh A, Middleton MR, Rees S, Barker RW.

BMC Health Serv Res. 2018 May 31;18(1):393. doi: 10.1186/s12913-018-3162-2. Erratum in: BMC Health Serv Res. 2019 Mar 28;19(1):198.

29.

The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors.

Smit AK, Newson AJ, Morton RL, Kimlin M, Keogh L, Law MH, Kirk J, Dobbinson S, Kanetsky PA, Fenton G, Allen M, Butow P, Dunlop K, Trevena L, Lo S, Savard J, Dawkins H, Wordsworth S, Jenkins M, Mann GJ, Cust AE.

Contemp Clin Trials. 2018 Jul;70:106-116. doi: 10.1016/j.cct.2018.05.014. Epub 2018 May 23.

PMID:
29802966
30.

Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature.

Schwarze K, Buchanan J, Taylor JC, Wordsworth S.

Genet Med. 2018 Oct;20(10):1122-1130. doi: 10.1038/gim.2017.247. Epub 2018 Feb 15.

PMID:
29446766
31.

Accurate costs of blood transfusion: a microcosting of administering blood products in the United Kingdom National Health Service.

Stokes EA, Wordsworth S, Staves J, Mundy N, Skelly J, Radford K, Stanworth SJ.

Transfusion. 2018 Apr;58(4):846-853. doi: 10.1111/trf.14493. Epub 2018 Jan 30.

PMID:
29380872
32.

The EQ-5D-5L is a valid approach to measure health related quality of life in patients undergoing bariatric surgery.

Fermont JM, Blazeby JM, Rogers CA, Wordsworth S; By-Band-Sleeve Study Management Group.

PLoS One. 2017 Dec 18;12(12):e0189190. doi: 10.1371/journal.pone.0189190. eCollection 2017.

33.

Diagnostic and therapeutic medical devices for safer blood management in cardiac surgery: systematic reviews, observational studies and randomised controlled trials.

Murphy GJ, Mumford AD, Rogers CA, Wordsworth S, Stokes EA, Verheyden V, Kumar T, Harris J, Clayton G, Ellis L, Plummer Z, Dott W, Serraino F, Wozniak M, Morris T, Nath M, Sterne JA, Angelini GD, Reeves BC.

Southampton (UK): NIHR Journals Library; 2017 Sep.

34.

Randomized trial of near-infrared spectroscopy for personalized optimization of cerebral tissue oxygenation during cardiac surgery.

Rogers CA, Stoica S, Ellis L, Stokes EA, Wordsworth S, Dabner L, Clayton G, Downes R, Nicholson E, Bennett S, Angelini GD, Reeves BC, Murphy GJ.

Br J Anaesth. 2017 Sep 1;119(3):384-393. doi: 10.1093/bja/aex182.

35.

Surgery versus surveillance in ulcerative colitis patients with endoscopically invisible low-grade dysplasia: a cost-effectiveness analysis.

Parker B, Buchanan J, Wordsworth S, Keshav S, George B, East JE.

Gastrointest Endosc. 2017 Dec;86(6):1088-1099.e5. doi: 10.1016/j.gie.2017.08.031. Epub 2017 Sep 4.

36.

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes.

Morrell L, Wordsworth S, Fu H, Rees S, Barker R.

BMC Health Serv Res. 2017 Aug 30;17(1):613. doi: 10.1186/s12913-017-2561-0.

37.

Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis.

Buchanan J, Wordsworth S, Clifford R, Robbe P, Taylor JC, Schuh A, Knight SJL.

Pharmacoeconomics. 2017 Aug;35(8):845-858. doi: 10.1007/s40273-017-0519-z.

38.

Adaptation of the By-Band randomized clinical trial to By-Band-Sleeve to include a new intervention and maintain relevance of the study to practice.

Rogers CA, Reeves BC, Byrne J, Donovan JL, Mazza G, Paramasivan S, Andrews RC, Wordsworth S, Thompson J, Blazeby JM, Welbourn R; By-Band-Sleeve study investigators.

Br J Surg. 2017 Aug;104(9):1207-1214. doi: 10.1002/bjs.10562.

39.

Erratum to: What Are the Real Procedural Costs of Bariatric Surgery? A Systematic Literature Review of Published Cost Analyses.

Doble B, Wordsworth S, Rogers CA, Welbourn R, Byrne J, Blazeby JM; By-Band-Sleeve Trial Management Group.

Obes Surg. 2017 Aug;27(8):2193. doi: 10.1007/s11695-017-2768-5. No abstract available.

40.

What Are the Real Procedural Costs of Bariatric Surgery? A Systematic Literature Review of Published Cost Analyses.

Doble B, Wordsworth S, Rogers CA, Welbourn R, Byrne J, Blazeby JM; By-Band-Sleeve Trial Management Group.

Obes Surg. 2017 Aug;27(8):2179-2192. doi: 10.1007/s11695-017-2749-8. Review. Erratum in: Obes Surg. 2017 Aug;27(8):2193.

41.

Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics.

Morrell L, Wordsworth S, Rees S, Barker R.

Pharmacoeconomics. 2017 Aug;35(8):793-804. doi: 10.1007/s40273-017-0511-7. Review.

42.

Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.

Hamblin A, Wordsworth S, Fermont JM, Page S, Kaur K, Camps C, Kaisaki P, Gupta A, Talbot D, Middleton M, Henderson S, Cutts A, Vavoulis DV, Housby N, Tomlinson I, Taylor JC, Schuh A.

PLoS Med. 2017 Feb 14;14(2):e1002230. doi: 10.1371/journal.pmed.1002230. eCollection 2017 Feb.

43.

A Core Outcome Set for the Benefits and Adverse Events of Bariatric and Metabolic Surgery: The BARIACT Project.

Coulman KD, Hopkins J, Brookes ST, Chalmers K, Main B, Owen-Smith A, Andrews RC, Byrne J, Donovan JL, Mazza G, Reeves BC, Rogers CA, Thompson JL, Welbourn R, Wordsworth S, Blazeby JM; BARIACT working group.

PLoS Med. 2016 Nov 29;13(11):e1002187. doi: 10.1371/journal.pmed.1002187. eCollection 2016 Nov.

44.

StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.

Neffendorf JE, Desai R, Wang Y, Kelly J, Murphy C, Reeves BC, Chakravarthy U, Wordsworth S, Lewis C, Peacock J, Uddin S, O'Sullivan JM, Jackson TL.

Trials. 2016 Nov 24;17(1):560.

45.

The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES): a virtual randomised balanced incomplete block trial.

Reeves BC, Scott LJ, Taylor J, Hogg R, Rogers CA, Wordsworth S, Townsend D, Muldrew A, Peto T, Violato M, Dakin H, Cappel-Porter H, Mills N, O'Reilly D, Harding SP, Chakravarthy U.

Health Technol Assess. 2016 Oct;20(80):1-120.

46.

Cost-effectiveness of community versus hospital eye service follow-up for patients with quiescent treated age-related macular degeneration alongside the ECHoES randomised trial.

Violato M, Dakin H, Chakravarthy U, Reeves BC, Peto T, Hogg RE, Harding SP, Scott LJ, Taylor J, Cappel-Porter H, Mills N, O'Reilly D, Rogers CA, Wordsworth S.

BMJ Open. 2016 Oct 24;6(10):e011121. doi: 10.1136/bmjopen-2016-011121.

47.

Design and implementation of the AIRWAYS-2 trial: A multi-centre cluster randomised controlled trial of the clinical and cost effectiveness of the i-gel supraglottic airway device versus tracheal intubation in the initial airway management of out of hospital cardiac arrest.

Taylor J, Black S, J Brett S, Kirby K, Nolan JP, Reeves BC, Robinson M, Rogers CA, Scott LJ, South A, Stokes EA, Thomas M, Voss S, Wordsworth S, Benger JR.

Resuscitation. 2016 Dec;109:25-32. doi: 10.1016/j.resuscitation.2016.09.016. Epub 2016 Sep 30.

48.

A Comparison of Health Professionals' and Patients' Views of the Importance of Outcomes of Bariatric Surgery.

Coulman KD, Howes N, Hopkins J, Whale K, Chalmers K, Brookes S, Nicholson A, Savovic J, Ferguson Y, Owen-Smith A, Blazeby J; By-Band-Sleeve Trial Management Group, Blazeby J, Welbourn R, Byrne J, Donovan J, Reeves BC, Wordsworth S, Andrews R, Thompson JL, Mazza G, Rogers CA.

Obes Surg. 2016 Nov;26(11):2738-2746.

49.

A multicentre randomised controlled trial of Transfusion Indication Threshold Reduction on transfusion rates, morbidity and health-care resource use following cardiac surgery (TITRe2).

Reeves BC, Pike K, Rogers CA, Brierley RC, Stokes EA, Wordsworth S, Nash RL, Miles A, Mumford AD, Cohen A, Angelini GD, Murphy GJ.

Health Technol Assess. 2016 Aug;20(60):1-260. doi: 10.3310/hta20600.

50.

Are lower levels of red blood cell transfusion more cost-effective than liberal levels after cardiac surgery? Findings from the TITRe2 randomised controlled trial.

Stokes EA, Wordsworth S, Bargo D, Pike K, Rogers CA, Brierley RC, Angelini GD, Murphy GJ, Reeves BC; TITRe2 Investigators.

BMJ Open. 2016 Aug 1;6(8):e011311. doi: 10.1136/bmjopen-2016-011311.

Supplemental Content

Loading ...
Support Center